Aptorum Group announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to generate protein and microRNA blood-based biomarker data focused on Alzheimer’s disease.
The analysis will use well-characterized plasma samples whose amyloid status was determined by amyloid PET and will measure biomarkers including p-Tau 217, amyloid 42/40, neurofilament light (NfL) and other analytes, and will evaluate these panels alone and in combination with DiamiR’s CogniMIR platform.
DiamiR will conduct testing in its CLIA-certified, CAP-accredited laboratory and aims to expand non-invasive brain health biomarker offerings for clinical testing and biopharma services.
The announcement also reiterates that Aptorum and DiamiR entered a definitive merger agreement on 16 July 2025, and that shareholders of both companies approved the merger on 9 June 2026; completion remains subject to customary closing conditions and is expected before fiscal 2027.
Upon closing, DiamiR is slated to become a wholly owned subsidiary and the combined entity will be renamed Niki BioSolutions, Inc., according to the company.
